These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7158390)

  • 1. Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
    Johansson P
    Acta Physiol Scand; 1982 Sep; 116(1):37-40. PubMed ID: 7158390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and biochemical effects of L-DOPA in the sea-gull, Larus argentatus.
    Johansson P; Hermansson LE; Henning M
    Eur J Pharmacol; 1983 Mar; 87(4):475-80. PubMed ID: 6852101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
    Wilke WL
    Pediatr Res; 1983 Nov; 17(11):924-5. PubMed ID: 6359046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central action of L-DOPA in blood pressure regulation and effect on catecholamine content in the frog, Xenopus laevis.
    Henning M; Johansson P
    Comp Biochem Physiol C Comp Pharmacol; 1981; 70(1):117-21. PubMed ID: 6117402
    [No Abstract]   [Full Text] [Related]  

  • 5. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs.
    Blair ML; Reid IA; Ganong WF
    J Pharmacol Exp Ther; 1977 Jul; 202(1):209-15. PubMed ID: 874815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
    Antonaccio MJ; Kerwin L
    J Pharmacol Exp Ther; 1976 Feb; 196(2):380-8. PubMed ID: 1255483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of L-DOPA on blood pressure and catecholamine content in the brain and peripheral organs in the Atlantic cod, Gadus morhua.
    Johansson P; Henning M
    Comp Biochem Physiol C Comp Pharmacol; 1981; 70(2):249-53. PubMed ID: 6118224
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies on the enzymatic blood-brain barrier: quantitative measurements of DOPA decarboxylase in the wall of microvessels as related to the parenchyma in various CNS regions.
    Hardebo JE; Falck B; Owman C; Rosengren E
    Acta Physiol Scand; 1979 Apr; 105(4):453-60. PubMed ID: 452922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of L-dihydroxyphenylalanine on rat behavior and on catecholamine metabolism of the brain in rats with different degrees of emotional-behavioral reactivity].
    Bondarenko NA; Miroshnichenko II; Kudrin VS; Bondarenko NA
    Biull Eksp Biol Med; 1988 Aug; 106(8):168-70. PubMed ID: 3416051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interactions of cerebral serotonin and catecholamines].
    Watanabe Y
    Nihon Yakurigaku Zasshi; 1983 May; 81(5):365-83. PubMed ID: 6195056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs.
    Lovinger R; Holland J; Kaplan S; Grumbach M; Boryczka AT; Shackelford R; Salmon J; Reid IA; Ganong WF
    Neuroscience; 1976 Dec; 1(6):443-50. PubMed ID: 11370235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of L-dopa on human muscle sympathetic nerve activity.
    Takeuchi S; Sugiyama Y; Mano T; Iwase S; Matsukawa T
    Environ Med; 1993; 37(1):99-102. PubMed ID: 12269353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of L-DOPA on aggressive behavior and central monoaminergic activity in the lizard Anolis carolinensis, using a new method for drug delivery.
    Höglund E; Korzan WJ; Watt MJ; Forster GL; Summers TR; Johannessen HF; Renner KJ; Summers CH
    Behav Brain Res; 2005 Jan; 156(1):53-64. PubMed ID: 15474650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.